Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Ceftibuten dihydrate, a third-generation cephalosporin antibiotic, is the dihydrate form of ceftibuten which is a semisynthetic, beta-lactamase-stable, cephalosporin with antibacterial activity. Ceftibuten inactivates penicillin-binding proteins located on the inner membrane of the bacterial cell wall. This results in the weakening of the bacterial cell wall and causes cell lysis.
Targets |
β-lactam
|
---|---|
ln Vitro |
Ceftibuten (Sch-39720) exhibits moderate activity against Serratia sp.and Streptococcus pyogenes, but is highly active against Haemophilus influenza, Escherichia coli, Klebsiella sp., and Proteus sp. Ceftibuten only exhibits weak activity against Pseudomonas aeruginosa and obligate anaerobes, and it is comparatively inactive against enterococci and staphylococci. With the exception of Bacteroides fragilis, it remains stable when most β-lactamase-producing organisms are present. Ceftibuten exhibits high potency against Enterobacteriaceae strains (mean MIC for 90% of strains = 0.25 μg/ml); however, it has comparatively lower efficacy against Campylobacter jejuni strains (mean MIC for 90% of strains = 16.0 μg/ml)[1].
|
ln Vivo |
Ceftibuten is a biologically stable β-lactam antibiotic that has been demonstrated to exhibit distinct stereoselective and proton-gradient dependent transport characteristics in rat intestinal brush-border membrane vesicles. It has also been shown to be transported by the small peptide transport system and to have a relatively high affinity for the carrier[3].
|
References |
|
Molecular Formula |
C15H18N4O8S2
|
---|---|
Molecular Weight |
446.4554
|
Elemental Analysis |
C, 40.35; H, 4.06; N, 12.55; O, 28.67; S, 14.36
|
CAS # |
118081-34-8
|
Related CAS # |
Ceftibuten;97519-39-6;Ceftibuten hydrate;1346153-47-6
|
Appearance |
Solid powder
|
SMILES |
C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O.O.O
|
InChi Key |
SSWTVBYDDFPFAF-ODPSPGRDSA-N
|
InChi Code |
InChI=1S/C15H14N4O6S2.2H2O/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19;;/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25);2*1H2/b6-1+;;
|
Chemical Name |
(6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;dihydrate
|
Synonyms |
Sch 39720 dihydrate; Sch-39720 dihydrate; Sch39720 dihydrate; Ceftibuten Dihydrate; UNII-62F4443RWP; Seftem; ceftibuten.2H2O; Seftem (TN); Cedax (TN); AC1NQZPM; SCHEMBL159144; CHEBI:34618; HY-B0698A; 62F4443RWP; AKOS025149353; AN-6406; HE068843; HE299817; O441; FT-0664440; D02121; A803878; I06-1263
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~223.98 mM)
DMSO : 90~100 mg/mL (201.58~223.98 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.60 mM) Solubility in Formulation 4: 2.26 mg/mL (5.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2398 mL | 11.1992 mL | 22.3984 mL | |
5 mM | 0.4480 mL | 2.2398 mL | 4.4797 mL | |
10 mM | 0.2240 mL | 1.1199 mL | 2.2398 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.